 |
|
Researchers Explore New Anti-HIV Agents
Joan Stephenson, PhD
JAMA. 2002;287:1635-1637.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Seattle—While antiretroviral drugs have done much to extend the lives of people infected with HIV, severe adverse effects and rising levels of drug resistance can limit their usefulness and are driving efforts to develop new anti-HIV medications. Building on knowledge of HIV gleaned from laboratory studies of the virus, researchers are developing and testing a host of promising new anti-HIV agents, according to findings unveiled here at the Ninth Annual Retrovirus Conference.
| |
Current anti-HIV drugs inhibit reverse transcriptase (nucleoside reverse transcriptase inhibitors [NRTIs] and nonnucleoside reverse transcriptase inhibitors [NNRTIs]) or protease. Anti-HIV drugs under development (blue) include agents that interfere with other steps in the HIV life cycle (entry inhibitors and integrase inhibitors) and a second-generation NNRTI.
|
|
Some prospective candidates in the drug development pipeline are compounds with a novel mechanism of action. Others are more potent versions of currently available classes of antiretroviral drugs that . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors
Labrosse et al.
J. Virol. 2002;77:1610-1613.
ABSTRACT
| FULL TEXT
|
